JPWO2020180741A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020180741A5 JPWO2020180741A5 JP2021549902A JP2021549902A JPWO2020180741A5 JP WO2020180741 A5 JPWO2020180741 A5 JP WO2020180741A5 JP 2021549902 A JP2021549902 A JP 2021549902A JP 2021549902 A JP2021549902 A JP 2021549902A JP WO2020180741 A5 JPWO2020180741 A5 JP WO2020180741A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- target
- item
- stranded
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000523 sample Substances 0.000 claims description 125
- 238000000034 method Methods 0.000 claims description 103
- 238000001514 detection method Methods 0.000 claims description 101
- 108091034117 Oligonucleotide Proteins 0.000 claims description 97
- 239000000090 biomarker Substances 0.000 claims description 86
- 206010028980 Neoplasm Diseases 0.000 claims description 74
- 201000011510 cancer Diseases 0.000 claims description 66
- 238000003556 assay Methods 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 102000003960 Ligases Human genes 0.000 claims description 13
- 108090000364 Ligases Proteins 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 102000018697 Membrane Proteins Human genes 0.000 claims description 11
- 108010052285 Membrane Proteins Proteins 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 102000005917 R-SNARE Proteins Human genes 0.000 claims description 10
- 108010005730 R-SNARE Proteins Proteins 0.000 claims description 10
- 230000003321 amplification Effects 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 210000004602 germ cell Anatomy 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 206010069754 Acquired gene mutation Diseases 0.000 claims description 2
- 102000004506 Blood Proteins Human genes 0.000 claims description 2
- 108010017384 Blood Proteins Proteins 0.000 claims description 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 230000004077 genetic alteration Effects 0.000 claims description 2
- 231100000118 genetic alteration Toxicity 0.000 claims description 2
- 238000003125 immunofluorescent labeling Methods 0.000 claims description 2
- 238000011528 liquid biopsy Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 238000007481 next generation sequencing Methods 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 238000003753 real-time PCR Methods 0.000 claims description 2
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 2
- 230000037439 somatic mutation Effects 0.000 claims description 2
- 238000011477 surgical intervention Methods 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 11
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000008191 permeabilizing agent Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 238000010384 proximity ligation assay Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962812878P | 2019-03-01 | 2019-03-01 | |
| US62/812,878 | 2019-03-01 | ||
| US202062962722P | 2020-01-17 | 2020-01-17 | |
| US62/962,722 | 2020-01-17 | ||
| PCT/US2020/020529 WO2020180741A1 (en) | 2019-03-01 | 2020-02-28 | Systems, compositions, and methods for target entity detection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022521781A JP2022521781A (ja) | 2022-04-12 |
| JPWO2020180741A5 true JPWO2020180741A5 (enrdf_load_stackoverflow) | 2023-03-09 |
| JP7344973B2 JP7344973B2 (ja) | 2023-09-14 |
Family
ID=72338354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549902A Active JP7344973B2 (ja) | 2019-03-01 | 2020-02-28 | 標的実体を検出するためのシステム、組成物、及び方法 |
Country Status (9)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220155304A1 (en) | 2019-03-01 | 2022-05-19 | Mercy Bioanalytics, Inc. | Systems, compositions, and methods for target entity detection |
| EP4301782A1 (en) | 2021-03-05 | 2024-01-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| WO2023004081A1 (en) * | 2021-07-21 | 2023-01-26 | Mercy Bioanalytics, Inc. | Compositions and methods for detection of esophageal cancer |
| US20240368701A1 (en) * | 2021-07-21 | 2024-11-07 | Mercy Bioanalytics, Inc. | Compositions and methods for cancer detection |
| WO2023004079A2 (en) * | 2021-07-21 | 2023-01-26 | Mercy Bioanalytics, Inc. | Compositions and methods for detection of liver cancer |
| CA3227131A1 (en) * | 2021-07-21 | 2023-01-26 | Mercy Bioanalytics, Inc. | Compositions and methods for detection of prostate cancer |
| WO2023004083A2 (en) * | 2021-07-21 | 2023-01-26 | Mercy Bioanalytics, Inc. | Compositions and methods for detection of bile duct cancer |
| EP4373962A2 (en) * | 2021-07-21 | 2024-05-29 | Mercy Bioanalytics, Inc. | Compositions and methods for detection of colorectal cancer |
| EP4373975A4 (en) * | 2021-07-21 | 2025-04-23 | Mercy Bioanalytics, Inc. | COMPOSITIONS AND METHODS FOR THE DETECTION OF PANCREATIC CANCER |
| CA3227119A1 (en) * | 2021-07-21 | 2023-01-26 | Mercy Bioanalytics, Inc. | Compositions and methods for detection of breast cancer |
| JP2024531915A (ja) | 2021-08-05 | 2024-09-03 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｍｕｃ抗体およびその使用 |
| JP2024536722A (ja) | 2021-09-03 | 2024-10-08 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｃｍｅｔ抗体およびその使用 |
| WO2023034571A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
| CN120584193A (zh) * | 2022-11-23 | 2025-09-02 | 润知生物技术公司 | 用于蛋白质分析物的检测的组合物和方法 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795714A (en) * | 1992-11-06 | 1998-08-18 | Trustees Of Boston University | Method for replicating an array of nucleic acid probes |
| CA2118759C (en) | 1993-04-21 | 2004-06-22 | William Jeffrey Allard | Diagnosis and monitoring of lung cancer patients by measurement of nca 50/90 in blood |
| US20020025519A1 (en) * | 1999-06-17 | 2002-02-28 | David J. Wright | Methods and oligonucleotides for detecting nucleic acid sequence variations |
| US7306904B2 (en) | 2000-02-18 | 2007-12-11 | Olink Ab | Methods and kits for proximity probing |
| WO2003044231A1 (en) | 2001-11-23 | 2003-05-30 | Simon Fredriksson | Method and kit for proximity probing with multivalent proximity probes |
| CA2522753C (en) | 2003-04-18 | 2014-06-10 | Becton, Dickinson And Company | Immuno-amplification |
| WO2004111271A2 (en) * | 2003-06-17 | 2004-12-23 | Keygene N.V. | Means and method for the detection of target nucleotide sequences using ligation assays with improved oligonucleotide probe pairs |
| EP1774035A4 (en) | 2004-06-14 | 2009-02-18 | Univ Leland Stanford Junior | METHOD AND COMPOSITIONS FOR USE FOR THE DETECTION OF ANALYTES USING APPROACH SENSORS |
| GB0605584D0 (en) | 2006-03-20 | 2006-04-26 | Olink Ab | Method for analyte detection using proximity probes |
| WO2007127848A1 (en) | 2006-04-26 | 2007-11-08 | University Of Louisville Research Foundation, Inc | Isolation of membrane vesicles from biological fluids and methods of using same |
| EP2728017B1 (en) | 2007-11-19 | 2016-08-24 | Celera Corporation | Lung cancer markers and uses thereof |
| US8481698B2 (en) | 2009-03-19 | 2013-07-09 | The President And Fellows Of Harvard College | Parallel proximity ligation event analysis |
| GB201004292D0 (en) | 2010-03-15 | 2010-04-28 | Olink Ab | Assay for localised detection of analytes |
| WO2012049316A1 (en) | 2010-10-15 | 2012-04-19 | Olink Ab | Dynamic range methods |
| EP2638057B1 (en) | 2010-11-10 | 2019-03-06 | Exosome Diagnostics, Inc. | Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom |
| GB201101621D0 (en) | 2011-01-31 | 2011-03-16 | Olink Ab | Method and product |
| WO2012155014A1 (en) | 2011-05-11 | 2012-11-15 | Exosome Diagnostics, Inc. | Nucleic acid extraction from heterogeneous biological materials |
| JP2014513557A (ja) * | 2011-05-17 | 2014-06-05 | ディクステリティー ダイアグノスティクス インコーポレイテッド | 標的核酸を検出する方法及び組成物 |
| GB201108678D0 (en) | 2011-05-24 | 2011-07-06 | Olink Ab | Multiplexed proximity ligation assay |
| US10174361B2 (en) | 2011-11-10 | 2019-01-08 | Exosome Diagnostics, Inc. | Cerebrospinal fluid assay |
| US9029086B2 (en) | 2012-01-26 | 2015-05-12 | Masood Kamali Moghaddam | Detection of single and multimodal analytes |
| EP2875158A4 (en) | 2012-07-18 | 2016-03-23 | Exosome Diagnostics Inc | USE OF MICROVESICLES IN THE DIAGNOSIS, FORECAST AND TREATMENT OF DISEASES AND MEDICAL SUDDEN |
| CN105025878A (zh) | 2012-10-03 | 2015-11-04 | 外来体诊断公司 | 微泡在医学疾病和病况的诊断、预后和治疗中的用途 |
| WO2014076214A1 (en) | 2012-11-14 | 2014-05-22 | Olink Ab | Rca reporter probes and their use in detecting nucleic acid molecules |
| CN104919057B (zh) | 2012-11-14 | 2018-09-25 | 欧凌科公司 | 基于rca的局部扩增方法 |
| US9086412B2 (en) | 2012-12-31 | 2015-07-21 | University Of Louisville Research Foundation, Inc. | Extracellular vesicle-associated protein markers of cancer |
| CN105026911B (zh) | 2013-01-03 | 2019-01-22 | 外来体诊断公司 | 用于分离微囊泡的方法 |
| CN106029900B (zh) | 2013-08-06 | 2020-02-28 | 外来体诊断公司 | 尿生物标志物群、基因表达特征及其使用方法 |
| KR20160080815A (ko) * | 2013-08-28 | 2016-07-08 | 카리스 라이프 사이언스 스위스 홀딩스 게엠베하 | 올리고뉴클레오티드 프로브 및 이의 용도 |
| WO2015047186A1 (en) | 2013-09-30 | 2015-04-02 | Di Wu | Methods to profile molecular complexes by using proximity bar-coding |
| GB201401885D0 (en) | 2014-02-04 | 2014-03-19 | Olink Ab | Proximity assay with detection based on hybridisation chain reaction (HCR) |
| WO2015130956A2 (en) | 2014-02-28 | 2015-09-03 | Exosome Sciences, Inc. | Brain specific exosome based diagnostics and extracorporeal therapies |
| KR102757668B1 (ko) * | 2014-05-15 | 2025-01-21 | 메소 스케일 테크놀러지즈, 엘엘시 | 개선된 분석 방법 |
| AU2015269103B2 (en) * | 2014-06-06 | 2021-12-23 | Cornell University | Method for identification and enumeration of nucleic acid sequence, expression, copy, or DNA methylation changes, using combined nuclease, ligase, polymerase, and sequencing reactions |
| WO2015193427A1 (en) | 2014-06-19 | 2015-12-23 | Olink Ab | Determination and analysis of biomarkers in clinical samples |
| WO2016093838A1 (en) * | 2014-12-11 | 2016-06-16 | New England Biolabs, Inc. | Enrichment of target sequences |
| US11175286B2 (en) * | 2015-01-09 | 2021-11-16 | Spot Biosystems Ltd. | Immunolipoplex nanoparticle biochip containing molecular probes for capture and characterization of extracellular vesicles |
| AU2016229076B2 (en) * | 2015-03-09 | 2022-01-20 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
| WO2017053516A1 (en) * | 2015-09-22 | 2017-03-30 | Trustees Of Boston University | Multiplexed phenotyping of nanovesicles |
| GB201518655D0 (en) | 2015-10-21 | 2015-12-02 | Olink Ab | Method for generating proximity probes |
| US10526665B2 (en) * | 2016-03-04 | 2020-01-07 | University Of Notre Dame Du Lac | Exosomal biomarkers diagnostic of tuberculosis |
| FI3464628T3 (fi) * | 2016-06-06 | 2024-05-03 | Redvault Biosciences Lp | Kohdereportterikonstruktit ja niiden käyttö |
| US11427864B2 (en) * | 2016-11-30 | 2022-08-30 | Exosome Diagnostics, Inc. | Methods and compositions to detect mutations in plasma using exosomal RNA and cell free DNA from non-small cell lung cancer patients |
| WO2018119455A1 (en) | 2016-12-23 | 2018-06-28 | Exosome Diagnostics, Inc. | Biofluid analysis and quantitation systems and methods |
| WO2019014486A1 (en) * | 2017-07-12 | 2019-01-17 | Exosome Diagnostics, Inc. | METHODS FOR ISOLATING AND ENRICHING POPULATIONS OF EXTRACELLULAR VESICLES DERIVED FROM BIOFLUIDS, AND METHODS OF USE THEREOF |
| WO2019018537A1 (en) | 2017-07-18 | 2019-01-24 | Exosome Diagnostics, Inc. | NUCLEIC ACID SEQUENCING ASSOCIATED WITH EXOSOMAL ISOLATION IN PATIENTS WITH MULTIPLE GLIOBLASTOMA |
| EP3660142A4 (en) | 2017-07-26 | 2021-05-05 | Rosetta Exosome | Method for isolating extracellular vesicles using cations |
| WO2019022542A2 (ko) | 2017-07-26 | 2019-01-31 | ㈜로제타엑소좀 | 양이온을 이용한 세포밖 소포체의 분리 방법 |
| WO2019066501A1 (ko) | 2017-09-27 | 2019-04-04 | ㈜로제타엑소좀 | 크기 배제 크로마토그래피를 이용한 세포밖 소포체의 분석 방법 및 이의 용도 |
| WO2019103548A2 (ko) | 2017-11-24 | 2019-05-31 | ㈜로제타엑소좀 | 반건식 크기 배제 크로마토그래피를 이용한 세포밖 소포체의 분리 방법 |
| WO2019113499A1 (en) * | 2017-12-07 | 2019-06-13 | The Broad Institute, Inc. | High-throughput methods for identifying gene interactions and networks |
| WO2019222708A2 (en) * | 2018-05-17 | 2019-11-21 | Meso Scale Technologies, Llc. | Methods for isolating surface marker displaying agents |
| EP3802884B1 (en) | 2018-06-06 | 2024-12-25 | Exosome Diagnostics, Inc. | Methods for developing urine biomarkers and for detecting bladder cancer |
| WO2019238944A1 (en) | 2018-06-15 | 2019-12-19 | Olink Proteomics Ab | Biomarker panel for ovarian cancer |
| EP3870348A1 (en) * | 2018-10-23 | 2021-09-01 | Meso Scale Technologies, LLC | Methods for isolating surface marker displaying agents |
| EP3884045B1 (en) | 2018-11-20 | 2023-01-11 | Exosome Diagnostics, Inc. | Methods for internal controls of microvesicle isolations |
| US20220155304A1 (en) | 2019-03-01 | 2022-05-19 | Mercy Bioanalytics, Inc. | Systems, compositions, and methods for target entity detection |
| AU2021209128A1 (en) * | 2020-01-17 | 2022-08-25 | Mercy Bioanalytics, Inc. | Compositions and methods for detection of ovarian cancer |
-
2020
- 2020-02-28 US US17/435,697 patent/US20220155304A1/en active Pending
- 2020-02-28 JP JP2021549902A patent/JP7344973B2/ja active Active
- 2020-02-28 SG SG11202109423TA patent/SG11202109423TA/en unknown
- 2020-02-28 AU AU2020233286A patent/AU2020233286B2/en active Active
- 2020-02-28 CA CA3129868A patent/CA3129868A1/en active Pending
- 2020-02-28 KR KR1020217031580A patent/KR102599718B1/ko active Active
- 2020-02-28 US US16/805,637 patent/US11085089B2/en active Active
- 2020-02-28 EP EP21201011.0A patent/EP3998349A3/en active Pending
- 2020-02-28 EP EP20766432.7A patent/EP3931351B1/en active Active
- 2020-02-28 WO PCT/US2020/020529 patent/WO2020180741A1/en unknown
- 2020-02-28 CN CN202080017641.1A patent/CN113748217B/zh active Active
-
2021
- 2021-03-17 US US17/204,773 patent/US20210214806A1/en active Pending
-
2022
- 2022-10-03 AU AU2022241629A patent/AU2022241629B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2492498T3 (es) | Panel de biomarcadores para el diagnóstico y la predicción de rechazo de injerto | |
| US20080206756A1 (en) | Biomarker panel for colorectal cancer | |
| US11827938B2 (en) | Methods of prostate cancer prognosis | |
| CN104620109A (zh) | 膀胱癌检测组合物、试剂盒及相关的方法 | |
| KR20120065959A (ko) | 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법 | |
| WO2017210372A1 (en) | Molecular tagging methods and sequencing libraries | |
| JP2009515553A (ja) | 癌の予知および予後と、癌治療のモニタリング | |
| EP1339872A2 (en) | Genetic markers for tumors | |
| US20230368915A1 (en) | Metastasis predictor | |
| JP2023533970A (ja) | 肺癌を検出するための組成物及び方法 | |
| JPWO2020180741A5 (enrdf_load_stackoverflow) | ||
| CN113493829B (zh) | 生物标志物在肺动脉高压诊疗中的应用 | |
| JP2010518868A (ja) | 前立腺癌の生存及び再発 | |
| WO2006062118A1 (ja) | 甲状腺乳頭癌の予後を予測するための新規のマーカー | |
| Macerola et al. | NanoString in the screening of genetic abnormalities associated with thyroid cancer | |
| CN113502326B (zh) | 基于生物标志物的肺动脉高压的诊断产品及其应用 | |
| WO2018186687A1 (ko) | 생물학적 시료의 핵산 품질을 결정하는 방법 | |
| CN108913772B (zh) | 基于捕获测序的bMSI检测技术 | |
| US20230175071A1 (en) | Liquid biopsy platform in plasma and saliva | |
| JP2024519082A (ja) | 肝細胞がんのｄｎａメチル化バイオマーカー | |
| US20230133776A1 (en) | Methods for diagnosing cancer | |
| JP2007532142A (ja) | 乳がん遺伝子発現バイオマーカー | |
| CN120138161B (zh) | 一种检测食管鳞癌标志物的试剂在制备食管鳞癌辅助诊断或诊断产品中的应用 | |
| US20250129428A1 (en) | Methods and materials for predicting the progression of prostate cancer and treating same | |
| JP2006166789A (ja) | 癌の新規診断方法 |